Literature DB >> 21357786

Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003).

Christine H Chung1, James J Dignam, M Elizabeth Hammond, Alexander C Klimowicz, Stephanie K Petrillo, Anthony Magliocco, Richard Jordan, Andy Trotti, Sharon Spencer, Jay S Cooper, Quynh-Thu Le, K Kian Ang.   

Abstract

PURPOSE: Glioma-associated oncogene family zinc finger 1 (GLI1) expression was assessed to determine a potential role of hedgehog (Hh) signaling in head and neck squamous cell carcinoma (HNSCC). Additional proteins known to be modulated by Hh signaling, including beta-catenin (CTNNB1) and epidermal growth factor receptor (EGFR), were also assessed to determine the correlation among these distinct signaling pathways. PATIENTS AND METHODS: Nuclear GLI1 and CTNNB1 expression levels were determined in tumors from patients enrolled on Radiation Therapy Oncology Group (RTOG) 9003, a radiation fractionation trial. The results were also correlated with previously determined EGFR expression. The expression levels were evaluated in relation to three end points: time to metastasis (TTM), time to disease progression (TDP), and overall survival (OS).
RESULTS: Among 1,068 eligible patients, data on GLI1, CTNNB1, and EGFR were available in 339, 164, and 300 patients, respectively. Although CTNNB1 expression did not differentiate prognosis, GLI1 was associated with poorer outcomes, adjusted for age, TNM stages, and Karnofsky performance score, and the significant influence persisted in a multivariable analysis (quartile 4 [Q4] v Q1 to Q3: TTM hazard ratio [HR], 2.7; 95% CI, 1.5 to 4.9; TDP HR, 1.6; 95% CI, 1.1 to 2.5; OS HR, 1.9; 95% CI, 1.4 to 2.7). The significance of GLI1 persisted in a multivariable analysis that included EGFR expression levels.
CONCLUSION: These data suggest that Hh signaling may play an important role in metastasis and that GLI1 could serve as a marker in HNSCC, but the regulatory mechanisms and oncogenic significance need further investigation. Risk classification based on this analysis needs a validation in independent cohorts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21357786      PMCID: PMC3084000          DOI: 10.1200/JCO.2010.32.3295

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  53 in total

1.  Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb.

Authors:  B Wang; J F Fallon; P A Beachy
Journal:  Cell       Date:  2000-02-18       Impact factor: 41.582

Review 2.  Hedgehog signaling in animal development: paradigms and principles.

Authors:  P W Ingham; A P McMahon
Journal:  Genes Dev       Date:  2001-12-01       Impact factor: 11.361

3.  Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened.

Authors:  James K Chen; Jussi Taipale; Michael K Cooper; Philip A Beachy
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

4.  Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer.

Authors:  D Neil Watkins; David M Berman; Scott G Burkholder; Baolin Wang; Philip A Beachy; Stephen B Baylin
Journal:  Nature       Date:  2003-03-05       Impact factor: 49.962

Review 5.  Hedgehog signaling: a tale of two lipids.

Authors:  P W Ingham
Journal:  Science       Date:  2001-11-30       Impact factor: 47.728

6.  Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma.

Authors:  Christine H Chung; Qiang Zhang; Elizabeth M Hammond; Andy M Trotti; Huijun Wang; Sharon Spencer; Hua-Zhong Zhang; Jay Cooper; Richard Jordan; Marvin H Rotman; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-21       Impact factor: 7.038

Review 7.  Hedgehog signaling: progenitor phenotype in small-cell lung cancer.

Authors:  D Neil Watkins; David M Berman; Stephen B Baylin
Journal:  Cell Cycle       Date:  2003 May-Jun       Impact factor: 4.534

8.  Medulloblastoma growth inhibition by hedgehog pathway blockade.

Authors:  David M Berman; Sunil S Karhadkar; Andrew R Hallahan; Joel I Pritchard; Charles G Eberhart; D Neil Watkins; James K Chen; Michael K Cooper; Jussi Taipale; James M Olson; Philip A Beachy
Journal:  Science       Date:  2002-08-30       Impact factor: 47.728

9.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

Authors:  K Kian Ang; Brian A Berkey; Xiaoyu Tu; Hua-Zhong Zhang; Ruth Katz; Elizabeth H Hammond; Karen K Fu; Luka Milas
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

10.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.

Authors:  J Taipale; J K Chen; M K Cooper; B Wang; R K Mann; L Milenkovic; M P Scott; P A Beachy
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

View more
  25 in total

Review 1.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers.

Authors:  Stephen G Chun; Hyunsil Park; Raj K Pandita; Nobuo Horikoshi; Tej K Pandita; David L Schwartz; John S Yordy
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

3.  Transient activation of hedgehog pathway rescued irradiation-induced hyposalivation by preserving salivary stem/progenitor cells and parasympathetic innervation.

Authors:  Bo Hai; Lizheng Qin; Zhenhua Yang; Qingguo Zhao; Lei Shangguan; Xinyu Ti; Yanqiu Zhao; Sangroh Kim; Dharanipathy Rangaraj; Fei Liu
Journal:  Clin Cancer Res       Date:  2013-10-22       Impact factor: 12.531

4.  Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.

Authors:  Gregory N Gan; Justin Eagles; Stephen B Keysar; Guoliang Wang; Magdalena J Glogowska; Cem Altunbas; Ryan T Anderson; Phuong N Le; J Jason Morton; Barbara Frederick; David Raben; Xiao-Jing Wang; Antonio Jimeno
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

5.  Induction of epithelial-mesenchymal transition (EMT) and Gli1 expression in head and neck squamous cell carcinoma (HNSCC) spheroid cultures.

Authors:  Nesrine Essid; Jean Claude Chambard; Amel Benammar Elgaaïed
Journal:  Bosn J Basic Med Sci       Date:  2018-11-07       Impact factor: 3.363

6.  Negative prognostic effect of low nuclear GLI1 expression in glioblastomas.

Authors:  Yuil Kim; In-Gu Do; Mineui Hong; Yeon-Lim Suh
Journal:  J Neurooncol       Date:  2017-04-17       Impact factor: 4.130

7.  Aberrant activation of hedgehog pathway in nasopharyngeal carcinoma.

Authors:  Yongjian Yue; Weide Zhong; Genwang Pei; Baiyu Xiao; Guoping Zhang; Funeng Jiang; Jinglin Zhang; Changhua Chen; Peizhou Yang; Hua Dang; Hong Chang
Journal:  Clin Exp Med       Date:  2012-07-20       Impact factor: 3.984

Review 8.  Role of anoctamins in cancer and apoptosis.

Authors:  Podchanart Wanitchakool; Luisa Wolf; Gudrun E Koehl; Lalida Sirianant; Rainer Schreiber; Sucheta Kulkarni; Umamaheswar Duvvuri; Karl Kunzelmann
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-02-03       Impact factor: 6.237

9.  A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.

Authors:  Daniel W Bowles; Stephen B Keysar; Justin R Eagles; Guoliang Wang; Magdalena J Glogowska; Jessica D McDermott; Phuong N Le; Dexiang Gao; Charles E Ray; Paul J Rochon; Dennis R Roop; Aik-Choon Tan; Hilary S Serracino; Antonio Jimeno
Journal:  Oral Oncol       Date:  2015-12-15       Impact factor: 5.337

10.  Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.

Authors:  Björn Schulze; Markus Meissner; Shahram Ghanaati; Iris Burck; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2015-10-08       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.